Days after the Department of Justice rescheduled state-licensed medical marijuana under the Controlled Substances Act, the Drug Enforcement Administration has…
Three years in the making, the legislative push to place xylazine under Schedule III of the federal Controlled Substances Act…
The Food and Drug Administration is asking the public to weigh in on the merits of commercial drug-disposal products, for…
On March 2, the Drug Enforcement Administration published a final rule permanently scheduling five benzodiazepines under the Controlled Substances Act.…
On December 3, the Drug Enforcement Administration launched Fentanyl Free America, “a comprehensive enforcement initiative and public awareness campaign aimed…
The Drug Enforcement Administration has raised aggregate production quotas (APQ) for the active ingredients in Adderall, Ritalin and Concerta, as…
The Drug Enforcement Administration is back with a new National Drug Threat Assessment, the annual report that returned in 2024…
The first hearings on the Biden administration’s marijuana rescheduling proposal that were set for late January have now been canceled following…
The 2020 National Drug Threat Assessment (NDTA) is such a widely cited document partly because it houses Drug Enforcement Administration…